ARTICLE | Product Development
Dendritic cell control
How Denceptor is targeting dendritic cells to fine tune T cell responses
February 24, 2017 11:11 PM UTC
Denceptor Therapeutics Ltd. is developing a technology for inducing antigen-specific T cell responses that the company believes will be more efficacious than other dendritic cell-targeted approaches for cancer while avoiding the safety issues raised by T cell therapies.
Founded in July 2016, Denceptor is a joint venture between Abzena plc in the U.K. and the Baylor Scott & White Research Institute in Dallas, Texas. The JV’s technology fuses a tumor antigen to an antibody targeting one of several receptors found on dendritic cells. The activated dendritic cells then internalize the antigen-antibody fusion, cleave the molecule and present the antigen portion to T cells. ...